SDF2L1 and hyperinsulinism: These findings suggest that treatment with the selective htr2b antagonist suppresses hyperglycemia, hyperinsulinemia, the increases in plasma FGF21 levels and hepatic FGF21, Sdf2l1, and htr2a expression in KKAy mice.